Aligos therapeutics presents clinical data from nash program at the 2023 paris hepatology conference

South san francisco, calif., march 29, 2023 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company presented phase 1 data for its thyroid receptor-beta (thr-ss) agonist candidate, alg-055009, at the 15th paris hepatology conference, taking place virtually march 27 – 29, 2023. the presentation will be available on the scientific presentations and conferences page on aligos' corporate website following the meeting.
ALGS Ratings Summary
ALGS Quant Ranking